Maven Securities LTD lowered its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 81.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 75,000 shares of the company's stock after selling 325,000 shares during the period. Maven Securities LTD's holdings in Roivant Sciences were worth $887,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ROIV. Barclays PLC lifted its holdings in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock worth $5,302,000 after buying an additional 75,609 shares in the last quarter. Elevate Capital Advisors LLC bought a new stake in shares of Roivant Sciences during the 4th quarter valued at about $2,116,000. Thompson Siegel & Walmsley LLC grew its position in shares of Roivant Sciences by 10.1% during the 4th quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock valued at $6,688,000 after buying an additional 51,705 shares during the last quarter. Russell Investments Group Ltd. grew its position in Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after purchasing an additional 1,948 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $995,000. Institutional investors and hedge funds own 64.76% of the company's stock.
Analysts Set New Price Targets
Several analysts recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.
Get Our Latest Stock Report on ROIV
Roivant Sciences Price Performance
Shares of NASDAQ:ROIV traded down $0.04 during trading on Monday, reaching $10.76. The stock had a trading volume of 941,534 shares, compared to its average volume of 5,573,706. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The business's 50-day moving average price is $10.51 and its 200 day moving average price is $11.07. The stock has a market capitalization of $7.67 billion, a PE ratio of -71.66 and a beta of 1.23.
Insider Transactions at Roivant Sciences
In related news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,116,345 shares of the company's stock, valued at approximately $11,409,045.90. This represents a 8.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the transaction, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,223,959 shares of company stock worth $13,420,035. Corporate insiders own 7.90% of the company's stock.
About Roivant Sciences
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
